Peter L. Salgo, MD: We have been teasing our viewers because we’ve been talking about novel therapies, something in the pipeline, something good…One of the new drugs is nusinersen. Peter L. Salgo, MD: ...

The patients, from 5 referral centers, were followed for at least 6 months and showed modest improvements in both motor and functional scales when treated with the antisense oligonucleotide for spinal ...

Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug ...

Medicines watchdog approves two treatments for patients with spinal muscular atrophy ...

Discover comprehensive details about Nusinersen, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adults The longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ...

Nusinersen injection is injected intrathecally (into the backbone) over 1-3 minutes so that it reaches the cerebrospinal fluid (CSF), the fluid that bathes the brain and the spinal cord. Dosage & When ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in ...

Monday - Friday, 6:00 - 7:00 PM ET Ionis Pharmaceutical shares jumped 30 percent on Monday on positive news of phase 3 data for its spinal muscular atrophy drug called Nusinersen, on which it ...